
Christopher Anzalone, Arrowhead Pharmaceuticals CEO
Updated: J&J returns rights to early-stage, RNAi NASH candidate to Arrowhead
J&J is handing the rights to a Phase I NASH candidate, stemming from a 2018 multibillion-dollar deal, back to its developer.
Arrowhead Pharmaceuticals
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.